135 related articles for article (PubMed ID: 28042794)
21. Breaking the vicious circle: Onabotulinum toxin A in children with therapy-refractory dysfunctional voiding.
't Hoen LA; van den Hoek J; Wolffenbuttel KP; van der Toorn F; Scheepe JR
J Pediatr Urol; 2015 Jun; 11(3):119.e1-6. PubMed ID: 25794865
[TBL] [Abstract][Full Text] [Related]
22. Transurethral ethanol injection therapy of benign prostatic hyperplasia: four-year follow-up.
Sakr M; Eid A; Shoukry M; Fayed A
Int J Urol; 2009 Feb; 16(2):196-201. PubMed ID: 19054163
[TBL] [Abstract][Full Text] [Related]
23. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin.
Yokoyama T; Yamamoto Y; Suzuki T; Oguma K; Nagai A
Acta Med Okayama; 2012; 66(4):291-7. PubMed ID: 22918201
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.
Park DS; Cho TW; Lee YK; Lee YT; Hong YK; Jang WK
Yonsei Med J; 2006 Oct; 47(5):706-14. PubMed ID: 17066515
[TBL] [Abstract][Full Text] [Related]
25. Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
Hsu YC; Wang HJ; Chuang YC
Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27128942
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ultrasound-guided transrectal ethanol injection for the treatment of benign prostatic hyperplasia in patients with high-risk comorbidities: a long-term study at a single tertiary care institution.
Li Y; Zhao Q; Dong L
Urology; 2014 Mar; 83(3):586-91. PubMed ID: 24581519
[TBL] [Abstract][Full Text] [Related]
27. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
[TBL] [Abstract][Full Text] [Related]
28. Prostatic arterial embolization for the treatment of lower urinary tract symptoms as a result of large benign prostatic hyperplasia: A prospective single-center investigation.
Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H; Wang Z
Int J Urol; 2015 Aug; 22(8):766-72. PubMed ID: 25950927
[TBL] [Abstract][Full Text] [Related]
29. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
Oeconomou A; Madersbacher H; Kiss G; Berger TJ; Melekos M; Rehder P
Eur Urol; 2008 Oct; 54(4):765-75. PubMed ID: 18571306
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of transurethral ethanol ablation of prostate for symptomatic benign prostatic hyperplasia.
Faruque MS; Alam MK; Ullah MA; Rahman MH; Kibria MG; Haque MM; Haque MA; Joarder AI; Paul BK
Mymensingh Med J; 2012 Apr; 21(2):265-9. PubMed ID: 22561769
[TBL] [Abstract][Full Text] [Related]
31. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
[TBL] [Abstract][Full Text] [Related]
32. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
[TBL] [Abstract][Full Text] [Related]
33. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
34. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis.
Pinto R; Lopes T; Silva J; Silva C; Dinis P; Cruz F
J Urol; 2013 Feb; 189(2):548-53. PubMed ID: 23253961
[TBL] [Abstract][Full Text] [Related]
35. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome).
Panicker JN; Seth JH; Khan S; Gonzales G; Haslam C; Kessler TM; Fowler CJ
BJU Int; 2016 May; 117(5):809-13. PubMed ID: 26435296
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).
Elshal AM; Elmansy HM; Elhilali MM
BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908
[TBL] [Abstract][Full Text] [Related]
37. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
38. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study.
Masumori N; Tsukamoto T; Horita H; Sunaoshi K; Tanaka Y; Takeyama K; Sato E; Miyao N
Int J Urol; 2013 Apr; 20(4):421-8. PubMed ID: 22989348
[TBL] [Abstract][Full Text] [Related]
39. Clinically and Statistically Significant Changes Seen in Sham Surgery Arms of Randomized, Controlled Benign Prostatic Hyperplasia Surgery Trials.
Welliver C; Kottwitz M; Feustel P; McVary K
J Urol; 2015 Dec; 194(6):1682-7. PubMed ID: 26143113
[TBL] [Abstract][Full Text] [Related]
40. Alterations in the Elasticity, Pliability, and Viscoelastic Properties of Facial Skin After Injection of Onabotulinum Toxin A.
Bonaparte JP; Ellis D
JAMA Facial Plast Surg; 2015; 17(4):256-63. PubMed ID: 25996589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
